QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-initiates-coverage-on-camp4-therapeutics-with-overweight-rating-announces-price-target-of-7

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating an...

 jp-morgan-downgrades-camp4-therapeutics-to-neutral

JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.

 piper-sandler-maintains-overweight-on-camp4-therapeutics-lowers-price-target-to-12

Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and lowers the price targ...

 camp4-therapeutics-secures-50m-initial-financing-with-potential-for-additional-50m-to-fund-syngap1-phase-12-clinical-trial

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investorsFinancing to provide $50 m...

 wedbush-initiates-coverage-on-camp4-therapeutics-with-outperform-rating-announces-price-target-of-8

Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform rating and announces Pric...

 camp4-unveils-syngap1-and-urea-cycle-disorder-data-at-asgct-2024-highlighting-protein-boost-and-safety-progress

CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th...

 camp4-therapeutics-q1-eps-062-up-from-2657-yoy-sales-85800k

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.62) per share. This is a 97.67 percent increase over losses o...

 camp4-announces-it-will-present-new-preclinical-data-from-its-urea-cycle-disorders-and-syngap1-related-disorders-programs-at-28th-american-society-of-gene-and-cell-therapy-annual-meeting-may13-17-2025-in-new-orleans-lousiana

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION